Angèle Maki
Angèle Maki, PhD, is a biopharmaceutical business development executive with more than 20 years of deal-making across emerging biotechs and global pharma. In December 2025 she became the first Chief Business Officer of Ability Biotherapeutics, a Montreal-based company building logic-gated antibodies with its generative-AI platform AbiLeap. A Stanford-trained biological chemist who started at the University of Winnipeg, she has held senior roles at Medarex, Bristol Myers Squibb, Genentech, 23andMe, Merck, Eli Lilly, ReCode Therapeutics and Callio Therapeutics, and chairs the non-profit Canadian Entrepreneurs in Life Sciences.
angele makiability biotherapeuticschief business officerbiotech business developmentantibodieslogic-gated antibodies